The mutational landscape of phosphorylation signaling in cancer

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Reimand, Jüri ^a   Wagih, Omar ^a   Bader, Gary D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; TUMOR PROTEIN;

ALGORITHM; BIOLOGY; GENE REGULATORY NETWORK; GENETICS; HUMAN; HUMAN GENOME; METABOLISM; MUTATION; NEOPLASM; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALGORITHMS; COMPUTATIONAL BIOLOGY; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84885100832     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02651     Document Type: Article

References (66)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
2. Northcott, P. A. et al. Subgroup-Specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56, doi:10.1038/nature11327 (2012).
3. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683-692, doi:10.1016/j.cell.2007.01.029 (2007).
4. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352, doi:10.1038/nature10983 (2012).
5. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558, doi:10.1126/science.1235122 (2013).
6. Futreal, P. A. et al. A census of human cancer genes. Nat Rev Cancer 4, 177-183, doi:10.1038/nrc1299 (2004).
7. Reimand, J. & Bader, G. D. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol 9, 637, doi:10.1038/msb.2012.68 (2013).
8. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068, doi:10.1038/nature07385 (2008).
9. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615, doi:10.1038/nature10166 (2011).
10. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70, doi:10.1038/nature11412 (2012).
11. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525, doi:10.1038/nature11404 (2012).
12. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337, doi:10.1038/nature11252 (2012).
13. Genomic and epigenomic landscapes of adult De novo acute myeloid leukemia. N Engl J Med 368, 2059-2074, doi:10.1056/NEJMoa1301689 (2013).
14. Kandoth, C. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73, doi:10.1038/nature12113 (2013).
15. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075, doi:10.1038/nature07423 (2008).
16. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160, doi:10.1126/science.1208130 (2011).
17. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507-2516, doi:10.1056/NEJMoa1103782 (2011).
18. Tiacci, E. et al. BRAF mutations in hairy-Cell leukemia. N Engl J Med 364, 2305-2315, doi:10.1056/NEJMoa1014209 (2011).
19. Smith, C. C. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485, 260-263, doi:10.1038/nature11016 (2012).
20. Morin, P. J. et al. Activation of beta-Catenin-Tcf signaling in colon cancer by mutations in beta-Catenin or APC. Science 275, 1787-1790 (1997).
21. Liu, Q. et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279, 52175-52182, doi:10.1074/jbc.M406802200 (2004).
22. Davydov, E. V. et al. Identifying a high fraction of the human genome to be under selective constraint using GERP11. PLoS Comput Biol 6, e1001025, doi:10.1371/journal.pcbi.1001025 (2010).
23. Liu, X., Jian, X. & Boerwinkle, E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. HumMutat 32, 894-899, doi:10.1002/humu.21517 (2011).
24. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 4, 1073-1081, doi:10.1038/nprot.2009.86 (2009).
25. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat Methods 7, 248-249, doi:10.1038/nmeth0410-248 (2010).
26. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes. Genome Res 19, 1553-1561, doi:10.1101/gr.092619.109 (2009).
27. Siepel, A., Pollard, K. S. & Haussler, D. in Proceedings of the 10th annual international conference on Research in Computational Molecular Biology 190-205 (Springer-Verlag, Venice, Italy, 2006).
28. Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates disease-Causing potential of sequence alterations. Nat Methods 7, 575-576, doi:10.1038/nmeth0810-575 (2010).
29. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478, doi:10.1038/nature10860 (2012).
30. Gu, T. L. et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640, doi:10.1371/journal. pone.0015640 (2011).
31. DiNitto, J. P. et al. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-Activation and its implication in sunitinib resistance. J Biochem 147, 601-609, doi:10.1093/jb/mvq015 (2010).
32. Dephoure, N. et al.Aquantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-10767, doi:10.1073/pnas.0805139105 (2008).
33. Olsen, J. V. et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3, doi:10.1126/scisignal.2000475 (2010).
34. Filippova, G. N. et al. Tumor-Associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-Binding specificity. Cancer Res 62, 48-52 (2002).
35. Bikkavilli, R. K., Feigin, M. E. & Malbon, C. C. p38 mitogen-Activated protein kinase regulates canonical Wnt-Beta-Catenin signaling by inactivation of GSK3beta. J Cell Sci 121, 3598-3607, doi:10.1242/jcs.032854 (2008).
36. Gwak, J. et al. Protein-Kinase-C-Mediated beta-Catenin phosphorylation negatively regulates the Wnt/beta-Catenin pathway. J Cell Sci 119, 4702-4709, doi:10.1242/jcs.03256 (2006).
37. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
38. Chadee, D. N. & Kyriakis, J. M. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat Cell Biol 6, 770-776, doi:10.1038/ncb1152 (2004).
39. Oswald, F. et al. SHARP is a novel component of theNotch/RBP-Jkappa signalling pathway. EMBO J 21, 5417-5426 (2002).
40. Shiohama, A., Sasaki, T., Noda, S., Minoshima, S. & Shimizu, N. Nucleolar localization of DGCR8 and identification of eleven DGCR8-Associated proteins. Exp Cell Res 313, 4196-4207, doi:10.1016/j.yexcr.2007.07.020 (2007).
41. Lejeune, F., Ishigaki, Y., Li, X. & Maquat, L. E. The exon junction complex is detected on CBP80-Bound but not eIF4E-Bound mRNA in mammalian cells: Dynamics of mRNP remodeling. EMBO J 21, 3536-3545, doi:10.1093/emboj/cdf345 (2002).
42. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res 38, e164, doi:10.1093/nar/gkq603 (2010).
43. Ward, J. J., McGuffin, L. J., Bryson, K., Buxton, B. F. & Jones, D. T. The DISOPRED server for the prediction of protein disorder. Bioinformatics 20, 2138-2139, doi:10.1093/bioinformatics/bth195 (2004).
44. Keshava Prasad, T. S. et al. Human Protein Reference Database-2009 update. Nucleic Acids Res 37, D767-772, doi:10.1093/nar/gkn892 (2009).
45. Hornbeck, P. V. et al. PhosphoSitePlus: A comprehensive resource for investigating the structure and function of experimentally determined posttranslational modifications in man and mouse. Nucleic Acids Res 40, D261-270, doi:10.1093/nar/gkr1122 (2012).
46. Dinkel, H. et al. Phospho.ELM: A database of phosphorylation sites-Update 2011. Nucleic Acids Res 39, D261-267, doi:10.1093/nar/gkq1104 (2011).
47. Punta, M. et al. The Pfam protein families database. Nucleic Acids Res 40, D290-301, doi:10.1093/nar/gkr1065 (2012).
48. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res 41, D816-823, doi:10.1093/nar/gks1158 (2013).
49. Hahn, W. C. &Weinberg, R. A. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2, 331-341, doi:10.1038/nrc795 (2002).
50. Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat Res 462, 247-253 (2000).
51. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat Med 10, 789-799, doi:10.1038/nm1087 (2004).
52. Higgins, M. E., Claremont, M.,Major, J. E., Sander, C. & Lash, A. E. CancerGenes: A gene selection resource for cancer genome projects. Nucleic Acids Res 35, D721-726, doi:10.1093/nar/gkl811 (2007).
53. Kel, A. E. et al. MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31, 3576-3579 (2003).
54. Reimand, J., Arak, T.&Vilo, J. g:Profiler-A web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res. 39, W307-315 (2011).
55. Ashburner, M. et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29, doi:10.1038/75556 (2000).
56. Matthews, L. et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 37, D619-622 (2009).
57. Ruepp, A. et al. CORUM: The comprehensive resource of mammalian protein complexes-2009. Nucleic Acids Res 38, D497-501, doi:10.1093/nar/gkp914 (2010).
58. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: A network-Based method for gene-Set enrichment visualization and interpretation. PLoS One 5, e13984, doi:10.1371/journal.pone.0013984 (2010).
59. Cline, M. S. et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2, 2366-2382, doi:10.1038/nprot. 2007.324 (2007).
60. Gonzalez-Perez, A. et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat. Methods. 10, 723-9. doi: 10.1038/nmeth.2562. (2013).
61. Reimand, J. et al. Domain-Mediated protein interaction prediction: From genome to network. FEBS Lett. 586, 2751-63. doi: 10.1016/j.febslet.2012.04.027 (2012).
62. Dees, N. D. et al. MuSiC: Identifying mutational significance in cancer genomes. Genome Res. 22, 1589-98, doi: 10.1101/gr.134635.111. (2012).
63. Gonzalez-Perez, A. et al. Functional impact bias reveals cancer drivers. Nucleic Acids Res. 40, e169, doi: 10.1093/nar/gks743. (2012).
64. Tamborero, D. et al. OncodriveCLUST: Exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics. 15, 2238-44, doi: 10.1093/bioinformatics/btt395 (2013).
65. Stuart, M. J. et al. The cancer genome atlas pan-Cancer analysis project.Nat. Genet. 45, 1113-1120 (2013).
66. Tamborero, D. et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep. 3, 2650; DOI: 10.1038/srep02650 (2013).